Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Other

January 14, 2022

Can Michael Davidson Strike Gold Again with NewAmsterdam’s CETPi?

Here is a brief preview of this blast: In early January 2022, Michael Davidson’s NewAmsterdam Pharma announced it has dosed the first patient in its Ph3 BROADWAY trial evaluating obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor in patients with HeFH or established ASCVD (view CT.gov record). Below FENIX provides brief thoughts on the NewAmsterdam obicetrapib program in the context of Michael Davidson’s other successful company exits.